Market Research Logo

Global Biosimilars and Follow-On Biologics Market 2019-2029

Global Biosimilars and Follow-On Biologics Market 2019-2029

The global biosimilars and follow-on biologics market is estimated to have reached $10.7bn in 2018 and expected to grow at a CAGR of 5.4% in the first half of the forecast period. The market is dominated by Biosimilar Monoclonal Antibodies, this submarket is estimated to hold 23% share of this market in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 283-page report you will receive 98 tables and 67 figures– all unavailable elsewhere.

The 283-page report provides clear detailed insight into the global biosimilars and follow-on biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Biosimilars and Follow-on Biologics Market forecasts from 2019-2029
  • Along with revenue prediction for the overall world market for biosimilars, our investigation shows forecasts to 2029 for 8 individual therapeutic submarkets:
  • Monoclonal antibodies (mAbs)
  • Fusion proteins
  • Insulin
  • Erythropoietin (EPO)
  • Granulocyte colony-stimulating factor (G-CSF)
  • Interferons
  • Growth hormones
  • Fertility hormones
  • This report also shows revenue to 2029 for 12 individual submarkets within the above segments:
  • Rituximab, infliximab, trastuzumab, adalimumab and bevacizumab
  • Human insulin, insulin analogues, insulin glargine and insulin lispro
  • Interferon alfa and interferon beta
  • Etanercept
  • Our analyses show individual revenue forecasts to 2029 for 12 national markets:
  • US
  • Japan
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • China
  • India
  • South Korea
  • Russia
  • Brazil
  • Our study discusses the leading companies that are involved in the biosimilars and follow-on biologics industry
  • Our study provides a SWOT analysis of the biosimilars and follow-on biologics market.
  • Our study discusses pressures, opportunities and other events affecting the biosimilars industry and market, including these influences:
  • Strategies for developing biosimilars – needs, demand, challenges and opportunities
  • Guidelines from regulators (FDA, EMA and others)
  • Patent challenges and data exclusivity for biopharmaceuticals
  • Needs and opportunities in developing biosimilar mAbs, including rising incidence of cancers and increasing demand for lower-cost biologicals
  • Developments in technology and operations for biosimilar drug production.
Visiongain’s study is intended for anyone requiring commercial analyses for the biosimilars and follow-on biologics market. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1 Report Overview
1.1 Biosimilar Overview
1.2 Biosimilars Market Segmentation
1.3 Why You Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report for?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQ)
1.9 Some Associated Reports
1.10 About Visiongain
2 An Introduction to Biosimilars and Biosimilar Drug Development
2.1 What are Biologics?
2.1.1 Biologics can be very effective but also very expensive
2.1.2 Brief history of biological drug development
2.1.3 Why are Biologics the most lucrative products in the global pharmaceutical market?
2.2 What are Biosimilars?
2.3 Brief History of Biosimilars
2.4 What are Interchangeable Biological Products and how do They Differ from Biosimilars?
2.4.1 FDA Guidelines on Prescription of Interchangeables vs Biosimilars
2.4.2 Where does the EMA Stand with Regard to Interchangeables?
2.4.3 Where do the EU5 and other European Countries Stand with Regard to Automatic Substitution?
2.4.4 Why Would Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars?
2.5 Main Segments of the Overall Biosimilars Market
3 The Global Biosimilars Market 2018-2028
3.1 The Global Biosimilars Market
3.2 Biosimilars as a Share of the Biologics Market, 2017
3.2.1 Seven of the Top Ten Best-Selling Drugs are Biologics
3.2.2 Outlook for the Overall Biologics Market
3.3 Global Biosimilars Market Forecast, 2017-2029
3.4 What will Drive Growth in the Biosimilars Market?
3.4.1 Health benefits associated with biosimilars
3.4.2 Patent related re-issue factors
3.4.3 Supportive government norms related to biosimilars
3.4.4 Growing demand from emerging economies
3.4.5 Increasing research and development activities
3.5 What Factors Can Restrain Sales Growth in the Biosimilars Market?
3.5.1 Complexity in development process
3.5.2 Intense competition
3.5.3 Availability of substitutes like biobetters and next-generation biologics
3.6 Summary of the Drivers and Restraints for the Global Biosimilars Market
3.7 Global Biosimilars Market Forecast by Submarket, 2017-2029
3.7.1 Leading Segments in the Biosimilars Market
3.7.2 How Will the Composition of the Market Change Over the Next Ten Years?
4 Outlook for Biosimilars in Leading Developed Markets, 2017-2029
4.1 The Leading National Biosimilar Submarkets
4.2 National Submarket Forecasts 2017-2029
4.3 How will the Regional Composition of the Global Market Change from 2017-2029?
4.4 US Biosimilars Market Outlook 2017-2029
4.4.1 Status of the US Market in 2014-2018
4.4.2 FDA Finalises Three New Guidelines on 351(k) Applications in April 2015
4.4.2.1 The History of the US’ Biosimilar Guidelines
4.4.3 FDA Finally Releases Guidance on Biosimilar Naming
4.4.4 Individual States Can Pass their Own Biosimilar Substitution Laws
4.4.5 US Biosimilars Market Forecast 2017-2029
4.5 The EU Biosimilar Market: History and Current Status
4.5.1 History of EMA Guidelines and Updates
4.5.2 Biosimilar Uptake in Europe Varies between Nations
4.5.3 European Biosimilars Market Forecast, 2017-2029
4.5.4 Inflectra and Remsima in Europe - Demonstrates a Path for Other Biosimilar mAbs
4.5.5 German Biosimilar Market Outlook, 2018
4.5.5.1 German Biosimilar Market Forecast, 2017-2029
4.5.6 French Biosimilars Market Outlook, 2018
4.5.6.1 Biosimilar Substitution Passed but Requires Decrees to Come into Effect, Expected Sometime This Year
4.5.6.2 French Biosimilar Market Forecast, 2017-2029
4.5.7 UK Biosimilar Market Outlook, 2018
4.5.7.1 UK Biosimilar Market Forecast, 2017-2029
4.5.8 Italian Biosimilars Market Outlook, 2018
4.5.8.1 Italian Biosimilars Market Forecast, 2017-2029
4.5.9 Spanish Biosimilars Market Outlook, 2018
4.5.9.1 Spanish Biosimilar Market Forecast, 2017-2029
4.5.10 Biosimilar Regulation in Japan and Currently Approved Biosimilars
4.5.10.1 Differences between the European and Japanese Guidelines
4.5.10.2 Currently Approved Biosimilars in Japan
4.5.10.3 Japanese Biosimilar Market Forecast, 2017-2029
5 Outlook for Biosimilars in Emerging Markets, 2017-2029
5.1 China and India Lead Biosimilar Revenues
5.2 Leading Emerging Biosimilar Markets Forecast, 2017-2029
5.3 Chinese Biosimilars Market Outlook, 2018
5.3.1 China Publishes Final Guidelines for Biosimilars
5.3.2 Biosimilars Account for less than Half of Biotech Revenues in China
5.3.3 Chinese Biosimilars Market Forecast, 2017-2029
5.4 Indian Biosimilars Market Outlook, 2018
5.4.1 CDSCO Guidelines Released in 2012
5.4.2 Indian Biosimilars Market Forecast, 2017-2029
5.5 South Korea’s Established Biosimilar Guidelines
5.5.1 Currently Approved Biosimilars in South Korea, 2018
5.5.2 South Korean Biosimilars Market Forecast, 2017-2029
5.6 Russian Biosimilars Market Outlook and Forecast, 2017-2029
5.7 Brazilian Biosimilar Regulation
5.7.1 Government eager to promote biosimilar development, and two major conglomerates, bionovis and orygen, are racing to produce biosimilars
5.7.2 Brazilian Biosimilars Market Forecast, 2017-2029
6 Biosimilar Monoclonal Antibodies: Submarket Forecast & Pipeline, 2017-2029
6.1 MAbs as part of the overall biologics market in 2018
6.2 Monoclonal Antibodies (mAbs): largest biologic submarket, with individual drugs accumulating multi-billion-dollar revenues
6.3 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast, 2017-2029
6.4 Drivers for the Biosimilar Monoclonal Antibodies Market
6.4.1 Product development on global scale
6.4.2 Elevated count of cancer patients
6.4.3 Rising need for cost effective treatments
6.4.4 Formulation of business strategies
6.5 Restraints for the Monoclonal Antibodies Market
6.5.1 Availability of substitutes
6.5.1.1 Growing demand for next-generation therapies
6.5.2 Challenges in R&D process
6.5.3 Patent related issues
6.6 Leading Targets for Biosimilar Development, 2017-2029
6.7 Biosimilar Rituximab
6.7.1 Rituxan: The First Anti-Cancer mAb
6.7.2 Approved Biosimilars and Rituxan Patent Expiry
6.7.2.1 Reditux (Dr. Reddy’s Laboratories): First Biosimilar Rituximab
6.7.2.2 MabTas (Intas Pharmaceutical): Another Indian Biosimilar
6.7.2.3 AcellBia (Biocad): The Leading Biosimilar Rituximab
6.7.2.4 Kikuzubam (PROBIOMED) – Faced Challenges
6.7.3 Biosimilar Rituximab Pipeline, 2017-2029
6.7.3.1 Terminated Developments
6.7.3.2 GP2013 (Sandoz): One of the Biggest Names in the Biosimilar Industry Throws its Hat into the Ring with Advanced Stage Candidate
6.7.3.3 BI 695500 (Boehringer Ingelheim)
6.7.3.4 MabionCD20 (Mabion): Focusing on Markets with High Demand
6.7.3.5 CT-P10 (Celltrion)
6.7.3.6 PF-05280586 (Pfizer)
6.7.4 Biosimilar Rituximab: Revenue Forecast 2017-2029
6.8 Biosimilar Infliximab
6.8.1 Remicade: Second Only to Humira
6.8.2 Approved Biosimilars and Remicade Patent Expiry: Uncertainty in the US after FDA Rejection
6.8.2.1 Inflectra and Remsima (Hospira and Celltrion)
6.8.2.2 Celltrion Speeds Ahead with US FDA Filing, and Inflectra Approved in Australia and Canada
6.8.2.3 Inflimab and BOW015 (Epirus Biopharmaceuticals and Ranbaxy Laboratories)
6.8.3 Biosimilar Infliximab Pipeline, 2017-2029
6.8.3.1 SB2 (Samsung Bioepis): Has been filed for EU Approval and Shows Positive Phase 3 Results
6.8.3.2 NI-071 (Nichi-Iko): Advanced Stages
6.8.3.3 ABP 710 (Amgen) & BX2922 (BioXpress Therapeutics)
6.8.4 Biosimilar Infliximab: Revenue Forecast 2017-2029
6.9 Biosimilar Trastuzumab
6.9.1 Herceptin: Another Jewel in Roche’s Cancer mAb Portfolio
6.9.2 Approved Biosimilars and Herceptin Patent Expiry
6.9.2.1 Hertraz and CanMab (Mylan and Biocon): The First to Win Approval
6.9.2.2 Herzuma (Celltrion)
6.9.3 Biosimilar Trastuzumab Pipeline, 2017-2029
6.9.3.1 BCD-022 (Biocad): Leading Biosimilar Rituximab Developer Tries its Hand at Trastuzumab
6.9.3.2 ABP 980 (Amgen and Allergan): CHMP Approval
6.9.3.3 PF-05280014 (Pfizer): FDA halts approval
6.9.3.4 SB3 (Samsung Bioepis) and BX2318 (BioXpress Therapeutics)
6.9.4 Biosimilar Trastuzumab: Revenue Forecast 2017-2029
6.10 Biosimilar Adalimumab
6.10.1 Humira – The World’s Best-Selling Prescription Drug
6.10.2 Approved Biosimilars and Humira Patent Expiry
6.10.2.1 Exemptia (Zydus Cadila): The First Biosimilar Adalimumab
6.10.3 Biosimilar Adalimumab Pipeline, 2017-2029
6.10.3.1 ABP 501 (Amgen and Allergan): Positive Phase 3 Results Released
6.10.3.2 GP2017 (Sandoz): Phase 3
6.10.3.3 BI 695501 (Boehringer Ingelheim)
6.10.3.4 SB5 (Samsung Bioepis)
6.10.4 Biosimilar Adalimumab: Revenue Forecast 2017-2029
6.11 Biosimilar Bevacizumab
6.11.1 Avastin: High Revenues and Late Patent Expiry
6.11.2 Biosimilar Bevacizumab Pipeline, 2017-2029
6.11.2.1 BCD-021 (Biocad)
6.11.2.2 ABP 215 (Amgen and Allergan): Approved
6.11.2.3 BI 695502 (Boehringer Ingelheim): Phase 3
6.11.2.4 PF-06439535 (Pfizer): Phase 3
6.11.3 Biosimilar Bevacizumab: Revenue Forecast, 2017-2029
7 Biosimilar Fusion Proteins: Submarket Forecast and Pipeline, 2017-2029
7.1 Scientific Background
7.2 Differentiating Fusion Proteins
7.3 Fusion Proteins as Part of the Overall Biologics Market
7.4 Biosimilar Fusion Proteins Market Forecast, 2017-2029
7.5 Biosimilar Etanercept, 2017-2029
7.5.1 Enbrel is the Leading Fusion Protein
7.5.2 Enbrel Granted Extended Patent Protection in the US, Patent has Expired in EU
7.5.3 Multiple Biosimilars Available in Emerging Markets
7.5.3.1 Brenzys / SB4 (Merck and Samsung Bioepis): First Product Approval to Result from Biosimilar Collaboration
7.5.3.2 Yi Sai Pu (Shanghai CP Guojian Pharmaceutical) and Qiangke (Shanghai Celgen Biopharmaceutical)
7.5.3.3 Etacept (Cipla) and Intacept (Intas Pharmaceuticals)
7.5.3.4 Davictrel / HD-203 (Hanwha Chemical and Merck KGaA)
7.5.4 Biosimilar Etanercept Pipeline
7.5.5 GP2015 (Sandoz)
7.5.5.1 Sandoz Goes in Early: FDA Accepts Application for GP2015, Despite the Fact that Enbrel Patents are not due to Expire any time soon
7.5.6 SB4 (Samsung Bioepis): EMA Accepts Application
7.5.6.1 Samsung Bioepis Releases Positive Phase 3 Data for SB4
7.5.7 CHS-0214 (Coherus Biosciences and Baxter)
7.5.8 TuNEX / ENIA11 (Mycenax Biotech / TSH Biopharm Corp): Phase 3 in Taiwan
7.5.9 LBEC0101 (LG Life Sciences): Phase 3
7.5.10 Biosimilar Etanercept: Revenue Forecast 2017-2029
7.6 Eylea and Biosimilar Aflibercept
7.7 Orencia and Biosimilar Abatacept
8 Biosimilar Insulin Submarket Outlook, 2017-2029
8.1 Insulin as Part of the Biological Drug Sector
8.2 30 Million People Expected to be diagnosed with Diabetes by 2030
8.3 Approved Insulin Biosimilars
8.4 Abasaglar / Basaglar / Insulin Glargine BS - The First Insulin Biosimilars to be approved in Developed Markets
8.5 EMA Releases Finalised Insulin Biosimilars Guideline
8.6 Basaglar Delayed in the US until End of 2016
8.7 Biosimilar Insulin Market and Submarkets Forecast, 2017-2029
8.8 Biosimilar Human Insulin Submarket, 2017-2029
8.8.1 A Submarket Mostly Restricted to Emerging Markets?
8.8.2 Biosimilar Human Insulin in China
8.8.3 Biosimilar Human Insulin in India
8.8.3.1 Wockhardt and Biocon - Given up on their Desire to Target the US and Europe?
8.8.4 Biosimilar Human Insulin in Russia
8.8.5 Biosimilar Human Insulin Submarket Forecast, 2017-2029
8.9 Biosimilar Insulin Analogues Submarket, 2017-2029
8.9.1 Available Biologic Insulin Analogues – Sanofi’s Lantus Tops Revenues
8.9.2 Insulin Glargine in the Main Biosimilar Target
8.9.2.1 Limited Development for the Other Targets
8.9.3 Insulin Market Leaders are Developing Ultra-Rapid Acting Insulin Analogues
8.9.3.1 Ultra-Long Acting Insulin also in Development
8.9.4 Mylan Partners with Biocon for Insulin Analogues
8.9.5 Biosimilar Insulin Analogue Revenue Forecast, 2017-2029
8.10 Biosimilar Insulin Glargine
8.10.1 Biosimilars in India and China
8.10.2 Biosimilar Insulin Glargine Pipeline
8.10.2.1 MK-1293 (Merck / Samsung Bioepis)
8.10.2.2 Mylan’s Insulin Glargine (Mylan and Biocon)
8.10.3 Biosimilar Insulin Glargine: Revenue Forecast, 2017-2029
8.11 Biosimilar Insulin Lispro
8.11.1 Currently Available Biosimilars
8.11.2 Much Smaller Pipeline than for Insulin Glargine
8.11.3 Biosimilar Insulin Lispro: Revenue Forecast, 2017-2029
9 Biosimilar Erythropoietins Submarket Outlook, 2017-2029
9.1 Three Products Lead the Biologic EPO Therapy Market
9.2 Safety Concerns for Erythropoietin-Stimulating Agents
9.3 The Challenge from Oral Therapies is coming
9.4 Treating Anaemia in Patients with CKD - the Leading Use of EPO Therapies
9.5 Biosimilar Epoetin Approvals in Europe
9.6 Epoetin Alfa Pipeline for the European Market
9.7 Trends in Uptake for Biosimilar Epoetins in Europe
9.8 Epoetin Alfa Pipeline for the US - Companies Preparing for Launch
9.8.1 Pfizer’s Retacrit Delayed after Response Letter from FDA
9.8.2 Binocrit / HX575 has Completed Trials
9.9 Biosimilar Epoetin in Japan
9.10 Biosimilar Epoetin in South Korea
9.11 Biosimilar Epoetin in India and China
9.12 Second-Generation EPO Biosimilars
9.13 No Mircera Biosimilars in Clinical Development
9.14 Biosimilar EPO Market Forecast, 2017-2029
10 Biosimilar G-CSF Submarket Outlook, 2017-2029
10.1 Amgen Leads the Branded Biologic G-CSF Market
10.2 Teva Launches Long-Acting Pegfilgrastim
10.3 Selected Filgrastim Biosimilars Approved Worldwide
10.3.1 The European G-CSF Biosimilars Market
10.3.1.1 Trends in Biosimilar Uptake across Europe
10.3.2 Tevagrastim (Teva): The First Biosimilar in Europe, Launched as Granix in the US
10.3.3 Nivestim (Hospira – Pfizer)
10.3.4 Zarzio (Sandoz): The Most Prescribed Biosimilar Therapy in Europe
10.3.5 Zarxio Becomes the First Biosimilar to be Approved in the US, Launched in September
10.3.6 Apotex: FDA has Accepted Applications for both its Biosimilar Filgrastim, and its Biosimilar Pegfilgrastim
10.3.7 Multiple Launches in Japan in Recent Years
10.3.8 Biosimilar Filgrastim and Pegfilgrastim in India
10.3.9 Biosimilars in Russia, China and Other Emerging Markets
10.4 Biosimilar G-CSF Market Forecast, 2017-2029
11 Biosimilar Interferons Submarket Outlook, 2017-2029
11.1 Interferons: Key Antiviral and MS Therapies since the 1990s
11.2 Leading Interferon Brands
11.3 Competition for the Multiple Sclerosis Market - Challenges for Interferon Beta Therapies
11.4 All-Oral Regimens will Challenge Interferon Alfa Therapy
11.4.1 However Oral Therapies will be Expensive
11.5 There are no Approved Biosimilars in Developed Markets
11.6 Biosimilar Interferon Market Forecast, 2017-2029
11.7 Biosimilar Interferon Alfa
11.7.1 Biosimilar Interferon Alfa – a Common Target in Developing Countries, Leading to Fragmented Markets
11.7.2 Biosimilar Peginterferon Alfa
11.7.3 Hepatitis Treatment Rates are Low
11.7.4 Biosimilar Interferon Alfa Submarket Forecast, 2017-2029
11.8 Biosimilar Interferon Beta
11.8.1 Biosimilars are Well-Established in Emerging Markets
11.8.2 Biosimilar Interferon Beta Pipeline
11.8.3 EMA Guidance
11.8.4 Long-Acting Interferon Beta
11.8.5 Biosimilar Interferon Beta Submarket Forecast, 2017-2029
12 Biosimilar Recombinant Hormones Submarket Outlook, 2017-2029
12.1 Human Growth Hormone: First Extracted in 1958
12.2 Biologic Growth Hormone Market in 2014 - Novo Nordisk and Pfizer Dominate
12.2.1 Novo Nordisk Aiming to Retain Dominance through FlexPro Device and NN8640 Somatropin Candidate
12.3 Biosimilar Growth Hormones
12.3.1 Omnitrope - Well Established in Developed Markets
12.4 Multiple Biosimilars Available Worldwide
12.4.1 Biosimilars Growth Hormones Outside of Asia
12.4.2 Biosimilar Growth Hormones in Asia
12.4.3 Biosimilar Uptake Varies by Region
12.5 Biosimilar Growth Hormones Market Forecast, 2017-2029
12.6 Fertility Hormones
12.6.1 Two Products Lead the Branded Fertility Hormone Market
12.6.2 Long-Acting Follicle Stimulating Hormone (FSH)
12.6.3 Branded Fertility Hormones Market Outlook
12.6.4 Available Biosimilar Fertility Hormones
12.6.5 Biosimilars Approved in Europe
12.6.5.1 Ovaleap (Teva)
12.6.5.2 Befomla (Finox Biotech) Approved in Europe, Undergoing Phase 3 for US
12.6.6 Rising Infertility to Drive Demand to 2028
12.6.7 Biosimilar Fertility Hormones Market Forecast, 2017-2029
13 Biosimilars: Qualitative Analysis and Industry Trends
13.1 SWOT Analysis of the Biosimilars Market
13.2 Biosimilars Market: Strengths
13.2.1 Cost effective nature
13.2.2 Adoption of biosimilars in developed region
13.2.3 Well established market
13.2.4 Outsourcing factors
13.3 Biosimilars Market: Weaknesses
13.3.1 High capital investment
13.3.2 Complex development procedure
13.3.3 Low demand from some regions
13.4 Biosimilars Market: Opportunities
13.4.1 Patent re-new factor
13.4.2 Increasing disease prevalence
13.4.3 Licensing Agreements
13.5 Threats
13.5.1 Alternative markets
13.5.2 Patent Issues
13.5.3 Market fragmentation
13.5.4 Long Market and Data Exclusivity Periods
13.5.5 Lack of marketing
13.6 Biosimilars Product Pipeline
14 Company Profiles
14.1 Amgen Inc.
14.2 Biocon Limited
14.3 Celltrion Healthcare Co. Ltd.
14.4 Dong-A Socio Holdings
14.5 Dr. Reddy’s Laboratories Ltd.
14.6 F Hoffmann-La Roche Ltd.
14.7 Pfizer Inc.
14.8 Stada Arzneimittel AG
14.9 Teva Pharmaceutical Industries Ltd.
14.10 Wockhardt Limited
15 Conclusions from Visiongain’s Research and Analysis
15.1 Rapid Growth Expected for this High-Potential Market
15.2 Biosimilar Monoclonal Antibodies to be the Fastest Growing Segment
15.3 A Range of Factors Will Stimulate Demand
15.4 Challenges Remain in Developing and Successfully Launching Biosimilars
Appendices
Some Associated Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1993
Table 3.1 Top Ten Best-Selling Drugs of 2017 (Within Overall Pharmaceutical Market): Revenues ($bn), Market Shares (%)
Table 3.2 Global Biosimilars Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2029
Table 3.3 Patent Status for Leading Biologics within the Overall Biologics Market, 2018
Table 3.4 Biosimilars Market Forecast by Product Type: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 4.1 Global Biosimilars Market by Region: Revenues ($bn), Market Share (%), 2018
Table 4.2 Biosimilars Market Forecast by Nations: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 4.3 U.S. Biosimilar Approvals To-Date, 2018
Table 4.4 US Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 4.5: European Biosimilar Approvals To-Date, 2018
Table 4.6 European Biosimilar Market Segmented by Leading Nations: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 4.7 Germany Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 4.8 France Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 4.9 UK Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 4.10 Italy Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 4.11 Spain Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 4.12 Japanese Biosimilar Approvals To-Date, 2018
Table 4.13 Japan Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 5.1 Leading Emerging Biosimilar Markets: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2017-2029
Table 5.2 China Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 5.3 India Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 5.4 Currently Approved Biosimilars in South Korea, 2016
Table 5.5 South Korea Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 5.6 Russia Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 5.7 Brazil Biosimilars Market: Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2029
Table 6.1 The Best-Selling mAbs of 2017: Revenue ($bn), 2017
Table 6.2 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2029
Table 6.3 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2029
Table 6.4 Patent Status of Five Leading mAbs, 2018
Table 6.5 Patent Status of Five Leading mAbs, 2018
Table 6.6 Past and Present GP2013 (Sandoz)Clinical Trials, 2018
Table 6.7 Ongoing BI 695500 (Boehringer Ingelheim) Clinical Trials, 2018
Table 6.8 Ongoing CT-P10 (Celltrion) Clinical Trials, 2018
Table 6.9 Past and Present PF-05280586 (Pfizer) Clinical Trials, 2018
Table 6.10 Biosimilar Rituximab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2029
Table 6.11 Biosimilar Infliximab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2029
Table 6.12 Ongoing PF-05280014 (Pfizer) Clinical Trials, 2018
Table 6.13 Biosimilar Trastuzumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2029
Table 6.14 Recent ABP 501 (Amgen and Allergan) Clinical Trials, 2018
Table 6.15 Ongoing BI 695501 (Boehringer Ingelheim) Clinical Trials, 2018
Table 6.16 Biosimilar Adalimumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2029
Table 6.17 Recent BCD-021 (Biocad) Clinical Trials, 2018
Table 6.18 Biosimilar Bevacizumab Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2029
Table 7.1 Biosimilar Fusion Proteins Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2029
Table 7.2 Amgen’s US Patents and Expiry Dates for Enbrel
Table 7.3 Ongoing CHS-0214 (Coherus Biosciences and Baxter) Clinical Trials, 2018
Table 7.4 Biosimilar Etanercept Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2028

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report